Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-331833      Publish Date : Wednesday, November 6, 2013 Visit : 2672

Intl. Congress form | International Congress Report | International Congress Report For Faculty | World Leish 5

World Leish 5
The Report of World Leish 5 by Dr.ali khamesiour
Application Code :
306-0213-0017
 
Created Date : Sunday, September 22, 2013Update Date : Saturday, November 02, 2013IP Address :194.225.208.59
Submit Date : Saturday, November 02, 2013Email : khamesipour@tums.ac.ir
Personal Information
Name : Ali
Surname : Khamesipour
School/Research center : Center for Research & Training in Skin Diseases & Leprosy
Possition : Professor
Tel : +98-21-88970657
E-mail : khamesipour@tums.ac.ir
Information of Congress
Title of the Congress : World Leish 5
Title of your Abstract : HIGH LEVELS OF ARSENIC AND LEAD IN A MEGLUMINE ANTIMONIATE PRODUCT USED IN .......A MIDDLE EASTERN COUNTRY 

TLR2 AND TLR4 IN CUTANEOUS LEISHMANIASIS CAUSED BY L. MAJOR 

DYNAMICS OF LEISHMANIA INFECTION AND POSSIBLE CORRELATION WITH ANTIBODY 

| IL-23 AND IL-27 LEVELS IN MACROPHAGES COLLECTED FROM PERIPHERAL BLOOD OF PATIENTS WITH HEALING VS NON-HEALING FORM OF CUTANEOUS LEISHMANIASIS 
Venue : Porto de Galinhas, Pernambuco, Brazil
From : Monday, May 13, 2013
To : Friday, May 17, 2013
Abstract(Please copy/paste the abstract send to the congress) : HIGH LEVELS OF ARSENIC AND LEAD IN A MEGLUMINE ANTIMONIATE PRODUCT USED IN .......A MIDDLE EASTERN COUNTRY 

TLR2 AND TLR4 IN CUTANEOUS LEISHMANIASIS CAUSED BY L. MAJOR 

DYNAMICS OF LEISHMANIA INFECTION AND POSSIBLE CORRELATION WITH ANTIBODY 

| IL-23 AND IL-27 LEVELS IN MACROPHAGES COLLECTED FROM PERIPHERAL BLOOD OF PATIENTS WITH HEALING VS NON-HEALING FORM OF CUTANEOUS LEISHMANIASIS 
Keywords of your Abstract : LEAD IN A MEGLUMINE ANTIMONIATE 
Treatment of cutaneous leishmanisis
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/11439/Forms/306/Sistema iCongresso_3.doc
The presentation : Oral
The Cover of Abstract book :
Published abstract in the abstract book with the related code :
Where has your abstract been indexed? : none
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : 4000
Delegates from which countries presented in the congress? : UK, USA, Germany, Turkey, Lybia, Tunesia, Muraku, Palestine, Canada, Brazil, Colombia, Spain, Portugal, Switzerland, France, Sweeden, Australia, Sudan, India, etc
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : WHO,DNDi
What were the responses to your talking points? Were specific questions or concerns raised? : it was an excellent presentation, about the source of Meglusan which is not known about the countries which use it and if WHO approved
If you met staff members, please list their full names & positions. : Prof. Carlos Costa, Prof. J. Show, etc
Please inform us if there are any follow up actions we need to talk with the members of the congress : Yes, following the congress we have communications in regard of leishmaniasis control and treatment and and Prof. A. Satuskar visitted Iran, he gave a lecture in School of Public health and we have visited cutaneous leishmaniasis patients at CRTSDL and in an endemic area and the patients were treated using heat therapy machine and now we are following the patients, at week 4-6 we will check the rate of efficacy and send the data and photos to Prof. Satuskar and others who are using the same machine
Your experiences about the travel processes(Providing ticket, accommodation,...) : Due to current situation everything was difficult, the hotel reservation was also so.
Please give a briefing of your own observations and outcomes of the congress: : The most special for the meeting was that we could meet many scientists around the world, I have met scientisits from different countries and endemic areas discussed with them different issues, I have discussed leishmanization with Prof. John David, Dr David Sacks and Dr. Steeve Reed. I have discussed the issue of using second generation vaccines with Dr. Steeve Reed, director of IDRI, USA and others, I have talked to Dr Musa Ahmad about the collaboration between Iran and Sudan in regard of Leishmaniasis projects and exchange students. I have met Prof. M. Ollete and discussed about the leishmaniasis cases with drug resistant in Iran and possibly collaboration in drug resistant. I deeply feel that we need to organize an Internation meeting on leishmanisis in Iran.